S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in

Meridian Bioscience Stock Forecast, Price & News

+0.37 (+1.64 %)
(As of 01/22/2021 12:00 AM ET)
Today's Range
Now: $22.97
50-Day Range
MA: $20.46
52-Week Range
Now: $22.97
Volume336,400 shs
Average Volume444,036 shs
Market Capitalization$990.54 million
P/E Ratio21.27
Dividend YieldN/A
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare and PediaStat brands; and urea breath testing for H. pylori under the BreathID brand. This segment also offers gastrointestinal assays, including tests for C. difficile, H. pylori, and certain foodborne pathogens; respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry assays for testing elevated levels of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. The company has a strategic collaboration with DiaSorin Inc. to sell H. pylori tests. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.
Meridian Bioscience logo


Overall MarketRank

1.63 out of 5 stars

Medical Sector

275th out of 1,923 stocks

Diagnostic Substances Industry

6th out of 32 stocks

Analyst Opinion: 2.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:VIVO



Sales & Book Value

Annual Sales$253.67 million
Cash Flow$1.47 per share
Book Value$5.78 per share


Net Income$46.19 million


Market Cap$990.54 million
Next Earnings Date2/5/2021 (Confirmed)
+0.37 (+1.64 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VIVO News and Ratings via Email

Sign-up to receive the latest news and ratings for VIVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions

How has Meridian Bioscience's stock price been impacted by Coronavirus?

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VIVO stock has increased by 257.2% and is now trading at $22.97.
View which stocks have been most impacted by COVID-19

Is Meridian Bioscience a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Meridian Bioscience?

Wall Street analysts have given Meridian Bioscience a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Meridian Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience CEO Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Meridian Bioscience's next earnings date?

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, February 5th 2021.
View our earnings forecast for Meridian Bioscience

How can I listen to Meridian Bioscience's earnings call?

Meridian Bioscience will be holding an earnings conference call on Friday, February 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings data on Wednesday, November, 18th. The company reported $0.19 EPS for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The company earned $64.15 million during the quarter, compared to the consensus estimate of $59.47 million. Meridian Bioscience had a net margin of 18.21% and a trailing twelve-month return on equity of 21.06%.
View Meridian Bioscience's earnings history

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its first quarter 2021 Pre-Market earnings guidance on Thursday, January, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $92-92 million, compared to the consensus revenue estimate of $78.71 million.

What price target have analysts set for VIVO?

3 brokerages have issued twelve-month price targets for Meridian Bioscience's stock. Their forecasts range from $26.00 to $30.00. On average, they expect Meridian Bioscience's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 21.9% from the stock's current price.
View analysts' price targets for Meridian Bioscience
or view Wall Street analyst' top-rated stocks.

Who are some of Meridian Bioscience's key competitors?

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

Who are Meridian Bioscience's key executives?

Meridian Bioscience's management team includes the following people:
  • Mr. John P. Kenny, Pres, CEO & Director (Age 53, Pay $1.66M)
  • Mr. Bryan Baldasare, Exec. VP, Chief Accounting Officer, CFO & Sec.
  • Dr. Lourdes G. Weltzien Ph.D., Exec. VP of Life Science Bus. Unit (Age 56, Pay $683.51k)
  • Mr. Tony Serafini-Lamanna, Exec. VP of Diagnostics (Age 58, Pay $655k)
  • Mr. Jeff Pinkston, Director of Corp. Fin.
  • Mr. Charles Wood, VP of Corp. Strategy, Bus. Devel. & Investor Relations
  • Melissa J. McCarey, VP of Global HR
  • Ms. Susan D. Rolih, Consultant (Age 72)
  • Ms. Melissa A. Lueke, Consultant (Age 58)

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.08%), Crossmark Global Holdings Inc. (0.07%) and Exchange Traded Concepts LLC (0.06%). Company insiders that own Meridian Bioscience stock include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith and John P Kenny.
View institutional ownership trends for Meridian Bioscience

Which institutional investors are selling Meridian Bioscience stock?

VIVO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Meridian Bioscience
or view top insider-selling stocks.

Which institutional investors are buying Meridian Bioscience stock?

VIVO stock was bought by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., and Exchange Traded Concepts LLC. Company insiders that have bought Meridian Bioscience stock in the last two years include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Dwight E Ellingwood, Felicia Williams, James M Anderson, John Mccune Jr Rice, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience
or or view top insider-buying stocks.

How do I buy shares of Meridian Bioscience?

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $22.97.

How big of a company is Meridian Bioscience?

Meridian Bioscience has a market capitalization of $990.54 million and generates $253.67 million in revenue each year. The company earns $46.19 million in net income (profit) each year or $1.07 on an earnings per share basis. Meridian Bioscience employs 750 workers across the globe.

What is Meridian Bioscience's official website?

The official website for Meridian Bioscience is www.meridianbioscience.com.

How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.

This page was last updated on 1/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.